NCT02902484View on ClinicalTrials.gov

Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

September 7, 2017

Primary Completion Date

October 26, 2021

Study Completion Date

October 26, 2021

Conditions
Cancer of Pancreas
Interventions
DRUG

Nintedanib

Nintedanib Monotherapy Followed by Combination Therapy of Nintedanib and Gemcitabine Plus nab-Paclitaxel

Trial Locations (1)

75063

University of Texas Southwestern Medical Center, Dallas

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

collaborator

The University of Texas Health Science Center at San Antonio

OTHER

collaborator

South Plains Oncology Consortium

NETWORK

lead

University of Texas Southwestern Medical Center

OTHER

NCT02902484 - Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter